Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03553082
Other study ID # BIO-2017-0276
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 18, 2018
Est. completion date May 28, 2021

Study information

Verified date August 2021
Source American University of Beirut Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: The removal of Laryngeal Mask Airway (LMA) in children may be associated with respiratory adverse events. The incidence of these adverse events may be influenced by the type of anesthesia maintenance. It is not clear whether Total Intravenous Anesthesia (TIVA) with propofol is associated with a lower incidence of respiratory events upon removal of LMA as compared to maintenance with sevoflurane. Specific Aim: The primary aim of this study is to compare the prevalence of respiratory adverse events following LMA removal in patient receiving TIVA versus sevoflurane inhalational anesthesia in a pediatric population aged between 6 month and 6 years old. Secondary outcomes include quality of induction, maintenance and emergence from anesthesia between the 2 groups as evidenced by ease of LMA insertion, absence of bucking or movement during the procedure, time to LMA removal, and absence of emergence agitation. Methods: In this prospective randomized clinical trial, children will be enrolled in one of two groups: Group 1 will receive propofol for induction and maintenance of anesthesia, Group 2 will receive sevoflurane for induction and maintenance of anesthesia. In both groups patients will be mechanically ventilated. At the end of the procedure, LMAs will be removed when patients are fully awake as defined by the return of reflexes, eye opening, and purposeful movements. Significance: Data comparing the influence of TIVA and sevoflurane on the occurrence of respiratory adverse events after LMA removal are limited. Both techniques are standard of care at our institution. However, as per our clinical observations, we hypothesize that TIVA is superior to sevoflurane. This study will identify the technique that provides optimal anesthetic conditions and improved patient's safety.


Recruitment information / eligibility

Status Completed
Enrollment 135
Est. completion date May 28, 2021
Est. primary completion date May 28, 2021
Accepts healthy volunteers No
Gender All
Age group 6 Months to 6 Years
Eligibility Inclusion Criteria: 1. Age: 6 months to 6 years old 2. Patients undergoing short duration procedure ( ? 2 hours) (such as polysite removal, closed reduction, eye examination, excluding thoracic and abdominal surgery) 3. American Society of Anesthesiologists (ASA): I-III 4. Patients undergoing LMA general anesthesia. (NPO, short procedures, patient without known airway abnormalities). 5. Parental consent Exclusion Criteria: 1. Age: more than 6 years old and less than 6 months 2. Patients having: Asthma, hyper reactive airway (Acute exacerbation) 3. Patients having recent respiratory tract infection within 2 weeks. 4. Patients with congenital heart disease 5. Patients not eligible for LMA (full stomach, hiatal hernia, known or predicted difficult airway, syndromic patient with facial or airway malformation, patient undergoing major abdominal or thoracic surgery) 6. Patients at high risk of aspiration 7. Anticipated difficult airway 8. Patient with neurologic disorders (children with known neurologic disorders: seizure, mental retardation, cerebral palsy) 9. Difficult LMA insertion (> 3 attempts)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sevoflurane
Fentanyl 2 µg/kg for induction of anesthesia and sevoflurane 2% for maintenance
Propofol
Propofol 5-6 mg/kg and fentanyl 2 µg/kg for induction of anesthesia and propofol 250-300 µg/kg/min for maintenance

Locations

Country Name City State
Lebanon American University of Beirut Beirut

Sponsors (1)

Lead Sponsor Collaborator
American University of Beirut Medical Center

Country where clinical trial is conducted

Lebanon, 

Outcome

Type Measure Description Time frame Safety issue
Primary Respiratory adverse outcomes Encountered respiratory adverse outcomes such as cough 2 hours
Secondary Time to emergence Emergence time defined as the time from discontinuation of the anesthetic agents until LMA removal. 2 hours
Secondary LMA insertion characteristics Number of attempts and time taken to insertion, as well as adverse events encountered during insertion. 2 hours
Secondary Quality of anesthesia Lack of movement, bucking, cough 2 hours
Secondary Emergence agitation 4 points scale: 1: calm, 2: not calm but easily consolable, 3: not easily calmed restless or moderately agitated, 4: combative, disoriented or excited. 2 hours
See also
  Status Clinical Trial Phase
Completed NCT02141412 - Intravenous Dexmedetomidine For The Quaity Of Emergence From General Anesthesia Phase 4
Completed NCT02375217 - "Low Dose Sugammadex Combined With Neostigmine and Glycopyrrolate Versus Full Dose Sugammadex for Reversal of Rocuronium-induced Neuromuscular Blockade: a Cost Saving Strategy" Phase 4
Recruiting NCT03200964 - OS Anesthesia Followup of All Bariatric Procedures at One Hospital
Recruiting NCT06334939 - Bispectral Index, Suppression Rate and Emergence Agitation in Spine Surgeries